NOVAVAX INC
About NOVAVAX INC
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.1B
- Net income
- $440.3M
- Total assets
- $1.2B
- Market cap
- $1.6B
- Gross margin
- 93.5%
- Operating margin
- 40.3%
- Net margin
- 39.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.1B
- Cost of revenue
- $73.0M
- Gross profit
- $1.1B
- Operating expenses
- $597.6M
- Operating income
- $452.8M
- Income tax
- $1.9M
- Net income
- $440.3M
- EPS (basic)
- $2.72
- EPS (diluted)
- $2.58
Balance sheet
- Total assets
- $1.2B
- Current assets
- $978.3M
- Total liabilities
- $1.3B
- Current liabilities
- $459.9M
- Shareholders’ equity
- -$127.8M
Cash flow
- Operating cash flow
- -$244.6M
- Investing cash flow
- -$78.3M
- Financing cash flow
- $27.7M
- Net cash flow
- -$289.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.6B
- P/E ratio
- 3.3
- EPS (diluted)
- $2.58
- Dividend yield
- 14.89%
- Shares outstanding
- 182.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 5, 1995
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $440.3M in FY2025.
- Revenue declined 2% from FY2021 to FY2025.
- Gross margin of 93.5%, net margin 39.2%.
- Trading 24% below its 52-week high.
- Pays a dividend yielding about 14.89% annually.
- Valued at a price-to-earnings (P/E) ratio of 3.3.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review NOVAVAX INC.
Write a review
News about NOVAVAX INC
News & sentiment via Polygon.io
